Pharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studies

Página do item simplificado
dc.contributor.authorPavanelli, Angelica Leticia Reis [UNESP]
dc.contributor.authorDe Menezes, Bruna Silva
dc.contributor.authorPereira, Erica Bianca Barbosa
dc.contributor.authorDe Souza Morais, Fabio Assuncao
dc.contributor.authorCirelli, Joni Augusto [UNESP]
dc.contributor.authorDe Molon, Rafael Scaf [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)
dc.contributor.institutionUniversidade Federal do Rio de Janeiro (UFRJ)
dc.date.accessioned2023-03-02T02:49:06Z
dc.date.available2023-03-02T02:49:06Z
dc.date.issued2022-01-01
dc.description.abstractPeriodontitis, a highly prevalent multicausal chronic inflammatory and destructive disease, develops as a result of complex host-parasite interactions. Dysbiotic bacterial biofilm in contact with the gingival tissues initiates a cascade of inflammatory events, mediated and modulated by the host's immune response, which is characterized by increased expression of several inflammatory mediators such as cytokines and chemokines in the connective tissue. If periodontal disease (PD) is left untreated, it results in the destruction of the supporting tissues around the teeth, including periodontal ligament, cementum, and alveolar bone, which lead to a wide range of disabilities and poor quality of life, thus imposing significant burdens. This process depends on the differentiation and activity of osteoclasts, the cells responsible for reabsorbing the bone tissue. Therefore, the inhibition of differentiation or activity of these cells is a promising strategy for controlling bone resorption. Several pharmacological drugs that target osteoclasts and inflammatory cells with immunomodulatory and anti-inflammatory effects, such as bisphosphonates, anti-RANK-L antibody, strontium ranelate, cathepsin inhibitors, curcumin, flavonoids, specialized proresolving mediators, and probiotics, were already described to manage inflammatory bone resorption during experimental PD progression in preclinical studies. Meantime, a growing number of studies have described the beneficial effects of herbal products in inhibiting bone resorption in experimental PD. Therefore, this review summarizes the role of several pharmacological drugs used for PD prevention and treatment and highlights the targeted action of all those drugs with antiresorptive properties. In addition, our review provides a timely and critical appraisal for the scientific rationale use of the antiresorptive and immunomodulatory medications in preclinical studies, which will help to understand the basis for its clinical application.en
dc.description.affiliationDepartment of Diagnosis and Surgery São Paulo State University-UNESP School of Dentistry
dc.description.affiliationDepartment of Clinical Dentistry Federal University of Rio de Janeiro
dc.description.affiliationUnespDepartment of Diagnosis and Surgery São Paulo State University-UNESP School of Dentistry
dc.identifierhttp://dx.doi.org/10.1155/2022/5832009
dc.identifier.citationBioMed Research International, v. 2022.
dc.identifier.doi10.1155/2022/5832009
dc.identifier.issn2314-6141
dc.identifier.issn2314-6133
dc.identifier.scopus2-s2.0-85130387956
dc.identifier.urihttp://hdl.handle.net/11449/241867
dc.language.isoeng
dc.relation.ispartofBioMed Research International
dc.sourceScopus
dc.titlePharmacological Therapies for the Management of Inflammatory Bone Resorption in Periodontal Disease: A Review of Preclinical Studiesen
dc.typeResenha
unesp.author.orcid0000-0003-0940-2906[1]
unesp.author.orcid0000-0002-7082-9290[5]
unesp.author.orcid0000-0003-1110-6233 0000-0003-1110-6233[6]

Arquivos

Coleções

Artigos - Diagnóstico e Cirurgia - FOAR